Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1.

Abstract	Angiotensin II (Ang II) type 2 (AT2) receptors are abundantly expressed not only in the fetal brain where they probably contribute to brain development, but also in pathological conditions to protect the brain against stroke; however, the detailed mechanisms are unclear. Here, we demonstrated that AT2 receptor signaling induced neural differentiation via an increase in MMS2, one of the ubiquitin-conjugating enzyme variants. The AT2 receptor, MMS2, Src homology 2 domain-containing protein-tyrosine phosphatase 1 (SHP-1), and newly cloned AT2 receptor-interacting protein (ATIP) were highly expressed in fetal rat neurons and declined after birth. Ang II induced MMS2 expression in a dose-dependent manner, reaching a peak after 4 h of stimulation, and this effect was enhanced with AT1 receptor blocker, valsartan, but inhibited by AT2 receptor blocker PD123319. Moreover, we observed that an AT2 receptor agonist, CGP42112A, alone enhanced MMS2 expression. Neurons treated with small interfering RNA of MMS2 failed to exhibit neurite outgrowth and synapse formation. Moreover, the increase in AT2 receptor-induced MMS2 mRNA expression was enhanced by overexpression of ATIP but inhibited by small interfering RNA of SHP-1 and overexpression of catalytically dominant-negative SHP-1 or a tyrosine phosphatase inhibitor, sodium orthovanadate. After AT2 receptor stimulation, ATIP and SHP-1 were translocated into the nucleus after formation of their complex. Furthermore, increased MMS2 expression mediates the inhibitor of DNA binding 1 proteolysis and promotes DNA repair. These results provide a new insight into the contribution of AT2 receptor stimulation to neural differentiation via transactivation of MMS2 expression involving the association of ATIP and SHP-1.
Authors	Jian-Mei Li, Masaki Mogi, Kana Tsukuda, Hirokazu Tomochika, Jun Iwanami, Li-Juan Min, Clara Nahmias, Masaru Iwai, Masatsugu Horiuchi
Journal	Molecular endocrinology (Baltimore, Md.) (Mol Endocrinol) Vol. 21 Issue 2 Pg. 499-511 (Feb 2007) ISSN: 0888-8809 [Print] United States
PMID	17068200 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Angiotensin II Type 2 Receptor Blockers Carrier Proteins Imidazoles Inhibitor of Differentiation Protein 1 Mtus1 protein, mouse Nerve Tissue Proteins Oligopeptides Pyridines Receptor, Angiotensin, Type 2 Tetrazoles Tumor Suppressor Proteins Angiotensin II CGP 42112A PD 123319 Vanadates Valsartan Protein Phosphatase 1 Protein Tyrosine Phosphatase, Non-Receptor Type 6 Ptpn6 protein, rat Ligases Ube2v2 protein, rat Valine
Topics	Angiotensin II (physiology) Angiotensin II Type 2 Receptor Blockers Animals Carrier Proteins (genetics, metabolism) Cell Differentiation Cell Nucleus (physiology) Cells, Cultured DNA Repair Imidazoles (pharmacology) Inhibitor of Differentiation Protein 1 (metabolism) Ligases (metabolism) Mice Nerve Tissue Proteins (metabolism) Neurites (physiology) Neurons (cytology, metabolism) Oligopeptides (pharmacology) Protein Phosphatase 1 Protein Transport Protein Tyrosine Phosphatase, Non-Receptor Type 6 (antagonists & inhibitors, metabolism) Pyridines (pharmacology) Rats Rats, Wistar Receptor, Angiotensin, Type 2 (agonists, metabolism) Signal Transduction Synapses (physiology) Tetrazoles (pharmacology) Transcriptional Activation Tumor Suppressor Proteins (genetics, metabolism) Valine (analogs & derivatives, pharmacology) Valsartan Vanadates (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!